See the DrugPatentWatch profile for lucentis
What is Briarcliff's Lucentis Injection?
Briarcliff offers a biosimilar version of ranibizumab, marketed under the brand name Lucentis [1]. This injection is used to treat several eye conditions, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular diseases [1][2].
How does Briarcliff's Lucentis work?
Briarcliff's biosimilar to Lucentis contains ranibizumab, a fragment of a monoclonal antibody. It works by inhibiting vascular endothelial growth factor A (VEGF-A), a protein that promotes the growth of abnormal blood vessels in the eye. By blocking VEGF-A, the injection helps to reduce leakage and swelling in the retina, thereby preserving or improving vision [1][2].
When does Lucentis patent protection end?
The patent situation for Lucentis is complex, with multiple patents covering different aspects of the drug. Information on specific patent expiry dates and any ongoing litigation can be found on DrugPatentWatch.com [3].
Can biosimilars of Lucentis be approved?
Yes, biosimilars of Lucentis can be approved. Regulatory agencies like the U.S. Food and Drug Administration (FDA) have pathways for approving biosimilar versions of biologic drugs, provided they demonstrate high similarity to the reference product and no clinically meaningful differences [4]. Briarcliff's product is an example of such an approved biosimilar [1].
What are the potential side effects of Lucentis injections?
Common side effects of Lucentis injections can include eye pain, increased intraocular pressure, floaters, and inflammation of the iris [1][2]. Serious but less common side effects can include retinal detachment, inflammation inside the eye, and infection [2].
How is Briarcliff's Lucentis injection administered?
Briarcliff's biosimilar to Lucentis is administered via intravitreal injection, meaning it is injected directly into the vitreous humor of the eye by a qualified healthcare professional [1][2].
What conditions does Lucentis treat?
Lucentis, including its biosimilar versions, is approved for treating:
* Wet age-related macular degeneration (AMD) [1][2]
* Diabetic macular edema (DME) [1][2]
* Macular edema following retinal vein occlusion (RVO) [1][2]
* Diabetic retinopathy [1][2]
What is the difference between Lucentis and its biosimilar?
A biosimilar is a biological product that is highly similar to an already approved biologic (the reference product) and has no clinically meaningful differences. Briarcliff's injection is a biosimilar to the reference product Lucentis. While they are highly similar in terms of safety, efficacy, and quality, they are not identical due to the inherent complexity of biological molecules [1][4].
Who manufactures Lucentis and its biosimilars?
The original Lucentis was developed by Genentech and Novartis [5]. Briarcliff is a manufacturer of a biosimilar version of Lucentis [1].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.fda.gov/
5. https://www.drugpatentwatch.com/